TD Cowen Initiates Coverage On Arrowhead Pharma with Outperform Rating
Portfolio Pulse from richadhand@benzinga.com
TD Cowen analyst Brendan Smith has initiated coverage on Arrowhead Pharma (NASDAQ:ARWR) with an Outperform rating.

July 21, 2023 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharma has been initiated with an Outperform rating by TD Cowen analyst Brendan Smith.
The initiation of coverage by a reputable analyst with an Outperform rating is generally a positive signal for the stock. It suggests that the analyst believes the company's stock will do better than others in the market. This could potentially attract more investors to the stock, driving up its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100